Clozapine-induced dopamine levels in the rat striatum and nucleus accumbens are not affected by muscarinic antagonism

European Journal of Pharmacology

Volumn 362, Issue 2-3, 1998, Pages 127-136

  Gray, Alex M ^a   Connick, Jonathan H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antipsychotics; Cholinergic; Clozapine; Dopamine; Microdialysis; Muscarinic receptor

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CARBACHOL; CLOZAPINE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HALOPERIDOL; HOMOVANILLIC ACID; MUSCARINIC RECEPTOR; SCOPOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIPSYCHOTIC AGENTS; CARBACHOL; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; CORPUS STRIATUM; DOPAMINE; DRUG INTERACTIONS; HALOPERIDOL; MALE; MICRODIALYSIS; MUSCARINIC ANTAGONISTS; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; SCOPOLAMINE;

EID: 0032409462     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00695-5     Document Type: Article

References (35)

1. Baldessarini, R.S., 1990. Drugs and the treatment of psychiatric disorders. In: Gilman, G.A., Rall, W.T., Nies, S.A., Taylor, P. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn., Pergammon, New York.
2. Chapman M.A., See R.E. Differential effects of unique profile antipsychotic drugs on extracellular amino acids in the ventral pallidum and globus pallidus of rats. J. Pharmacol. Exp. Ther. 277:1996;1586-1594.
3. Consolo S., Wu C.F., Fusi R. D-1 receptor-linked mechanism modulates cholinergic neurotransmission in the rat striatum. J. Pharmacol. Exp. Ther. 242:1987;300-305.
4. Damsma G., De Boer P., Westerink B.H.C., Fibiger H.C. Dopaminergic regulation of striatal cholinergic interneurones: an in vivo microdialysis study. Nauyn-Schmiedeberg's Arch. Pharmacol. 342:1990;523-527.
5. Damsma G., Westerink B.H.C., Fibiger H.C. Dopamine regulation of striatal cholinergic interneurones: an in vivo microdialysis study. Naunyn-Schmiedebergs Arch. Pharmacol. 342:1990;523-527.
6. 1 and N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 259:1991;1064-1072.
7. Delfs J.M., Anegawa N.J., Chesselet M.F. Glutamate decarboxylase messenger RNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience. 66:1995;67-80.
8. DeVeaugh-Geiss, J., 1982. Tardive dyskinesia: phenomenology, pathophysiology, and pharmacology. In: DeVeaugh-Geiss, J. (Ed.), Tardive Dyskinesia and Related Involuntary Movement Disorders. John Wright, London, pp. 1-15.
9. ++ mobilization and release of acetylcholine from guinea-pig neostriatal slices. Br. J. Pharmacol. 91:1987;287-297.
10. Hersch S.M., Levey A.I. Diverse pre- and post-synaptic expression of m1-m4 muscarinic receptor proteins in neurons and afferents in rat neostriatum. Life Sciences. 56:1995;931-938.
11. Harrison M.B., Tissot M., Wiley R.G. Expression of m1 and m4 muscarinic receptor mRNA in the striatum following a selective lesion of striatonigral neurons. Brain Research. 734:1996;323-326.
12. 1 receptors and their desensitization after chronic treatment. Eur. J. Pharmacol. 264:1994;55-60.
13. Ichikawa J., Meltzer H.Y. Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and nucleus accumbens. J. Pharmacol. Exp. Ther. 256:1991;348-357.
14. 1 receptors. J. Pharmacol. Exp. Ther. 266:1993;557-562.
15. Le Moine C., Tison F., Bloch B. D2-dopamine receptor gene expression by cholinergic neurons in the rat striatum. Neurosci. Lett. 117:1990;248-252.
16. Marien M.R., Richard J.W. Drug effects on the release of endogenous acetylcholine in vivo: measurement by intracerebral dialysis and gas chromatography-mass spectrometry. J. Neurochem. 56:1990;2016-2023.
17. Meltzer H.Y., Chai B.L., Thomson P.A., Yamamoto B.K. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J. Pharmacol. Exp. Ther. 268:1994;1452-1461.
18. Memo M., Missale C., Trivelli L., Spano F.P. Acute scopolamine decreases dopamine metabolism in rat hippocampus and frontal cortex. Eur. J. Pharmacol. 149:1988;367-370.
19. Miller S.R., Hiley R.C. Antimuscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature (London). 248:1974;596-597.
20. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, San Diego.
21. Protais P., Chagraoui A., Arbaoui J., Mocaër E. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents. Eur. J. Pharmacol. 271:1994;167-177.
22. Pucak P.M., Grace A.A. Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J. Pharmacol. Exp. Ther. 271:1994;1181-1192.
23. Rawls, S.M., McGinty, J.F., 1998. Muscarinic receptors regulate glutamate levels in the rat striatum: an in vivo microdialysis study. J. Pharmacol. Exp. Ther., in press.
24. Rivest R., Marsden C.A. Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by halperidol. Br. J. Pharmacol. 104:1991;234-238.
25. Santiago M., Westerink B.H.C. The regulation of dopamine release from nigralstriatal neurons in conscious rats: the role of somatodendritic autoreceptors. Eur. J. Pharmacol. 204:1991;79-85.
26. Smolders I., Bogaert L., Ebinger G., Michotte Y. Muscarinic modulation of striatal dopamine, glutamate, GABA release, as measured with in vivo microdialysis. J. Neurochem. 68:1997;1942-1948.
27. + stimulated release of acetylcholine from rat neostriatum. Brain Res. 250:1982;263-270.
28. Stoof J.C., Thieme R.E., Vrijmoed-De Vries M.C., Mulder A.H. In vitro acetylcholine release from the rat caudate nucleus as a new model for testing drugs with dopamine-receptor activity. Nauyn-Schmiedeberg's Arch. Pharmacol. 309:1979;119-124.
29. Wang J.Q., McGinty J.F. Intrastriatal injection of a muscarinic receptor agonist and antagonist regulates striatal neuropeptide mRNA expression in normal and amphetamine-treated rats. Eur. J. Pharmacol. 748:1997;62-70.
30. Wang J.Q., Jolkkonen M., McGinty J.F. The muscarinic toxin 3 augments neuropeptide mRNA in rat striatum in vivo. Eur. J. Pharmacol. 334:1997;43-47.
31. Westerink B.H.C., De Vries J.B. On the mechanism of neuroleptic induced increase in striatal dopamine release: brain dialysis provides direct evidence for mediation by autoreceptors localized on nerve terminals. Neurosci. Lett. 99:1989;197-202.
32. Westerink B.H.C., Santiago M., De Vries J.B. In vivo evidence for a concordant response of terminal and dendritic dopamine release during intranigral infusion of drugs. Naunyn-Schmiedeberg's Arch. Pharmacol. 346:1992;637-643.
33. Wolf, M.E., Deutch, A.Y., Roth, R.H., 1987. Pharmacology of central dopamine neurons. In: Henn, F.A., DeLisi, L.E. (Eds.), Handbook of Schizophrenia, Vol. 2, Neurochemistry and Neuropharmacology of Schizophrenia. Elsevier, New York, pp. 101-147.
34. Zetterström T., Sharp T., Ungerstedt U. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur. J. Pharmacol. 106:1985;27-37.
35. 4 receptor agonist. Eur. J. Pharmacol. (Molecular Pharmacol. Sect.). 269:1994;R1-R2.